Literature DB >> 17942870

Satisfaction guaranteed--"payment by results" for biologic agents.

Alan M Garber1, Mark B McClellan.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17942870     DOI： 10.1056/NEJMp078204

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Future costs and the future of cost-effectiveness analysis.

Authors:  Alan M Garber; Charles E Phelps
Journal:  J Health Econ       Date:  2008-05-03       Impact factor: 3.883

3.  Access with evidence development in the UK: past experience, current initiatives and future potential.

Authors:  Andrew Briggs; Karen Ritchie; Elisabeth Fenwick; Kalipso Chalkidou; Peter Littlejohns
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Comparative effectiveness research and evidence-based health policy: experience from four countries.

Authors:  Kalipso Chalkidou; Sean Tunis; Ruth Lopert; Lise Rochaix; Peter T Sawicki; Mona Nasser; Bertrand Xerri
Journal:  Milbank Q       Date:  2009-06       Impact factor: 4.911

5.  Expensive cancer drugs: a comparison between the United States and the United Kingdom.

Authors:  Ruth R Faden; Kalipso Chalkidou; John Appleby; Hugh R Waters; Jonathon P Leider
Journal:  Milbank Q       Date:  2009-12       Impact factor: 4.911

Review 6.  Sustainable Financing of Innovative Therapies: A Review of Approaches.

Authors:  Aidan Hollis
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

Review 7.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 8.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

9.  Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Authors:  Daniel A Goldstein; Bilal B Ahmad; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

10.  N-of-1 trials of expensive biological therapies: a third way?

Authors:  Richard L Kravitz; Naihua Duan; Richard H White
Journal:  Arch Intern Med       Date:  2008-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.